Key result
Periodontal pathogens may accelerate atherosclerosis via inflammation, highlighting mucosal vaccines and catechins as targets.
Inflammation is well accepted to play a crucial role in the development of atherosclerotic lesions, and recent studies have demonstrated an association between periodontal disease and cardiovascular disease. Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, causative agents of destructive chronic inflammation in the periodontium, can accelerate atheroma deposition in animal models. Emerging evidence suggests that vaccination against virulence factors of these pathogens and anti-inflammatory therapy may confer disease resistance. In this review, we focus on the role of inflammatory mechanisms and oxidative modification in the formation and activation of atherosclerotic plaques accelerated by P. gingivalis or A. actinomycetemcomitans in an ApoE-deficient mouse model and high-fat-diet-fed mice. Furthermore, we examine whether mucosal vaccination with a periodontal pathogen or the anti-inflammatory activity of catechins can reduce periodontal pathogen-accelerated atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Kurita‐Ochiai et al. (2014) conducted a review in Atherosclerosis and Periodontal disease. Periodontal pathogens, vaccination, and catechins was evaluated. Periodontal pathogens such as P. gingivalis and A. actinomycetemcomitans may accelerate atherosclerosis via inflammation, while mucosal vaccination and catechins offer potential therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: